Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 3 boards, counting each seat separately. Longest: Eledon Pharmaceuticals Inc., 3 years.
Eledon Pharmaceuticals Inc.
Director
Syndax Pharmaceuticals Inc.
Director
Emergent BioSolutions Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Eledon Pharmaceuticals Inc. June 10, 20250.0%
-
Emergent BioSolutions Inc. April 30, 202595.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 30, 2026 | Emergent BioSolutions Inc. | Grant or award | +25,344 | — | — |
| Apr 30, 2026 | Emergent BioSolutions Inc. | Open-market sale | −15,481 | $8.28 | $128,183 |
| Feb 4, 2026 | Syndax Pharmaceuticals Inc. | Grant or award | +24,000 | — | — |
| Jan 10, 2026 | Eledon Pharmaceuticals Inc. | Option exercise | +8,575 | — | — |
| May 23, 2025 | Emergent BioSolutions Inc. | Open-market sale | −7,844 | $6.30 | $49,417 |
| May 19, 2025 | Syndax Pharmaceuticals Inc. | Open-market purchase | +10,000 | $9.11 | $91,100 |
| Apr 30, 2025 | Emergent BioSolutions Inc. | Grant or award | +34,403 | — | — |
| Feb 5, 2025 | Syndax Pharmaceuticals Inc. | Grant or award | +25,000 | — | — |
| May 23, 2024 | Emergent BioSolutions Inc. | Grant or award | +17,430 | — | — |
| Feb 7, 2024 | Syndax Pharmaceuticals Inc. | Grant or award | +17,000 | — | — |
| May 25, 2023 | Emergent BioSolutions Inc. | Grant or award | +33,847 | — | — |
| Feb 2, 2023 | Syndax Pharmaceuticals Inc. | Grant or award | +16,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.